Jerome Alexandre
Overview
Explore the profile of Jerome Alexandre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
4137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
2.
Meyo M, Boudou-Rouquette P, Arrondeau J, Yu Chen J, Hirsch L, Neveux N, et al.
Clin Nutr ESPEN
. 2024 Sep;
64:44-50.
PMID: 39244156
Background & Aims: We previously reported in the ELY prospective study that increased resting energy expenditure (REE) - so-called hypermetabolism - worsened tumor response, 6-month progression-free (PFS) and overall survival...
3.
Kabirian R, Tredan O, Marme F, Paoletti X, Eberst L, Lebreton C, et al.
Future Oncol
. 2024 Aug;
20(35):2699-2708.
PMID: 39155847
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are...
4.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1025-1036.
PMID: 38963459
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim...
5.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, et al.
Br J Cancer
. 2024 Mar;
130(11):1866-1874.
PMID: 38532102
Background: Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model...
6.
Leroy K, Audigier Valette C, Alexandre J, Boussemart L, Chiesa J, Deldycke C, et al.
PLoS One
. 2023 Sep;
18(9):e0291495.
PMID: 37708140
Introduction: Considering the growing interest in matched cancer treatment, our aim was to evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least one targeted therapy...
7.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, et al.
Cancer Chemother Pharmacol
. 2023 Aug;
93(2):169-175.
PMID: 37620675
Purpose: Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our...
8.
Alexandre J, Le Frere-Belda M, Angelergues A, Ferron G, Treilleux I, Gaillard A, et al.
Bull Cancer
. 2023 Aug;
110(6S):6S34-6S43.
PMID: 37573037
Recommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a...
9.
Jeanne C, Treilleux I, Le Frere-Belda M, Alexandre J, Joly F, Rouleau E
Bull Cancer
. 2023 Aug;
110(6S):6S10-6S19.
PMID: 37573035
French recommendations for clinical practice Nice-Saint-Paul de Vence 2022-2023: histomolecular diagnosis of endometrial carcinomas The characterisation of endometrial carcinomas has been recently modified and enriched by molecular classification, the integration...
10.
Ashton E, Arrondeau J, Jouinot A, Boudou-Rouquette P, Hirsch L, Huillard O, et al.
Clin Nutr
. 2023 Apr;
42(6):944-953.
PMID: 37099986
Background & Aims: Sarcopenia has long been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with solid tumors. The creatinine-to-cystatin ratio (CC ratio, serum creatinine/cystatin...